《新股消息》康耐特光學(02276.HK)公開發售超購0.78倍及下限定價 一手中籤率50.38%
內地樹脂眼鏡鏡片製造商康耐特光學(02276.HK)公布招股結果,每股發售價定為4.46元,為招股價(4.46至6.1元)範圍下限定價,香港公開發售部分錄得超額認購約0.78倍。每手500股計,一手中籤率50.38%。該股將於明日(16日)掛牌。國泰君安為獨家保薦人。
公司是次上市料淨集約4.74億元,約46.4%將用於提高上海生產基地及江蘇生產基地的產能;約19.9%用於加強研發實力;約10.3%用於加大銷售及營銷力度;約10%用作營運資金及一般企業用途;約8.1%用於提升生產效率及工藝的技術;約5.3%用於償還銀行借款,該等借款主要用於撥付營運資金以支持集團的業務運作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.